PDS Biotechnology Corporation: 52-Week High Recently Eclipsed (PDSB)

IBN Spotlights
Friday, September 24, 2021 at 3:50pm UTC

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at $17.78, eclipsing its 52-week high. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is approximately 493,000 shares.

In the past 52 weeks, PDS Biotechnology Corporation share prices are bracketed by a low of $1.87 and a high of $17.78 and is now at $17.38, 829% above that low price.

There is potential upside of 61.8% for shares of PDS Biotechnology Corporation based on a current price of $17.38 and an average consensus analyst price target of $28.12.

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer